In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 65-76

  Hoshino, Kazuki ^a   Inoue, Kazue ^a   Murakami, Yoichi ^a   Kurosaka, Yuichi ^a   Namba, Kenji ^a   Kashimoto, Yoshinori ^a   Uoyama, Saori ^a   Okumura, Ryo ^a   Higuchi, Saito ^a   Otani, Tsuyoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 (7 AMINO 7 METHYL 5 AZASPIRO[2.4]HEPTAN 5 YL) 6 FLUORO 1 (2 FLUORO 1 CYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; 8 METHOXYFLUOROQUINOLONE DERIVATIVE; AZITHROMYCIN; CARBOXYLIC ACID DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DC 159A; GARENOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CHLAMYDOPHILA PNEUMONIAE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; GROWTH INHIBITION; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; MYCOPLASMA PNEUMONIAE; NONHUMAN; PEPTOSTREPTOCOCCACEAE; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ANALYSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICE; MICE, INBRED CBA; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 37849027971     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00853-07     Document Type: Article

References (31)

1. Ackermann, G., Y. J. Tang-Feldman, R. Schaumann, J. P. Henderson, A. C. Rodloff, J. Silva, and S. H. Cohen. 2003. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin. Microbiol. Infect 9:526-530.
2. Bast, D. J., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. C. de Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.
3. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.
4. Fridkin, S. K., J. C. Hageman, M. Morrison, L. T. Sanza, K. Como-Sabetti, J. A. Jernigan, K. Harriman, L. H. Harrison, R. Lynfield, and M. M. Farley. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
5. Fuller, J. D., and D. E. Low. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121.
6. Fuller, J. D., A. McGeer, and D. E. Low. 2005. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur. J. Clin. Microbiol. Infect. Dis. 24:780-788.
7. Golan, Y., L. A. McDermott, N. V. Jacobus, E. J. Goldstein, S. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, J. Rihs, P. Iannini, S. L. Gorbach, and D. R. Snydman. 2003. Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 52:208-213.
8. Greene, C. M., M. H. Kyaw, S. M. Ray, W. Schaffner, R. Lynfield, N. L. Barrett, C. Long, K. Gershman, T. Pilishvili, A. Roberson, E. R. Zell, C. G. Whitney, and N. M. Bennett. 2006. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin. Infect. Dis. 43:141-150.
9. Hoshino, K., R. Okumura, K. Inoue, Y Murakami, H. Awaya, T. Hirata, S. Yamachika, S. Higuchi, Y. Kashimoto, H. Haga, T. Otani, and K. Sato. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-0478.
10. Japan Society of Chemotherapy. 1992. Method for in vitro determination of chlamydial susceptibility - standard method of Japanese Society of Chemotherapy. Chemotherapy 40:308-314.
11. Japan Society of Chemotherapy. 1981. Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by agar dilution method. Chemotherapy 29:76-79.
12. Jimenez, M. R., J. L. Bellido, and J. A. Garcia Rodriguez. 2005. Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients. J. Clin. Microbiol. 43:1193-1197.
13. Kays, M. B., G. G. Zhanel, M. A. Reimann, J. Jacobi, G. A. Denys, D. W. Smith, and M. F. Wack. 2007. Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy 27:221-226.
14. Kupronis, B. A., C. L. Richards, and C. G. Whitney. 2003. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J. Am. Geriatr. Soc. 51:1520-1525.
15. Kyaw, M. H., R. Lynfield, W. Schaffner, A. S. Craig, J. Hadler, A. Reingold, A. R. Thomas, L. H. Harrison, N. M. Bennett, M. M. Farley, R. R. Facklam, J. H. Jorgensen, J. Besser, E. R. Zell, A. Schuchat, and C. G. Whitney. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:1455-1463.
16. LeBlanc, L., J. Pepin, K. Toulouse, M. F. Ouellette, M. A. Coulombe, M. P. Corriveau, and M. E. Alary. 2006. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg. Infect. Dis. 12:1398-1405.
17. Lim, S., D. Bast, A. McGeer, J. de Azavedo, and D. E. Low. 2003. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 9:833-837.
18. NCCLS. 2005. Performance standards for antimicrobial susceptibility testing; Fifteenth informational supplement. NCCLS, Wayne, PA.
19. Otani, T., M. Tanaka, E. Ito, Y. Kurosaka, Y. Murakami, K. Onodera, T. Akasaka, and K. Sato. 2003. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob. Agents Chemother. 47:3750-3759.
20. Pepin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P. Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V. Primeau, M. Nguyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
21. Sawatari, K., N. Ito, M. Nagasawa, H. Nakasato, H. Koga, K. Watanabe, et al. 1984. New susceptibility testing medium (B-SYE agar) for Legionella and Legionella-like organisms. Chemotherapy 32:718-723.
22. Schurek, K. N., H. J. Adam, C. G. Siemens, C. J. Hoban, D. J. Hoban, and G. G. Zhanel. 2005. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. J. Antimicrob. Chemother. 56: 769-772.
23. Shopsin, B., X. Zhao, B. N. Kreiswirth, G. S. Tillotson, and K. Drlica. 2004. Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int. J. Antimicrob. Agents 24:32-34.
24. Smith, H. J., A. M. Noreddin, C. G. Siemens, K. N. Schurek, J. Greisman, C. J. Hoban, D. J. Hoban, and G. G. Zhanel. 2004. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics. Antimicrob. Agents Chemother. 48: 3630-3635.
25. Tateda, K., K. Takashima, H. Miyazaki, T. Matsumoto, T. Hatori, and K. Yamaguchi. 1996. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob. Agents Chemother. 40:1520-1525.
26. Waites, K. B., Y. Rikihisa, and D. T. Robinson. 2003. Mycoplasma and Ureaplasma, p. 972-990. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, vol. 1, 8th ed. ASM Press, Washington, DC.
27. Weber, S. G., H. S. Gold, D. C. Hooper, A. W. Karchmer, and Y. Carmeli. 2003. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9:1415-1422.
28. Weigel, L. M., G. J. Anderson, R. R. Facklam, and F. C. Tenover. 2001. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:3517-3523.
29. Yamaguchi, K., and A. Ohno. 2005. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn. Microbiol. Infect. Dis. 52:135-143.
30. Yokota, S., K. Sato, O. Kuwahara, S. Habadera, N. Tsukamoto, H. Ohuchi, H. Akizawa, T. Himi, and N. Fujii. 2002. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob. Agents Chemother. 46:3311-3315.
31. Zhanel, G. G., S. Fontaine, H. Adam, K. Schurek, M. Mayer, A. M. Noreddin, A. S. Gin, E. Rubinstein, and D. J. Hoban. 2006. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treat. Respir. Med. 5:437-465.